Q4 2025 · 13F-HR
GILEAD SCIENCES, INC. (GILD)holdings as filed
Filed 2026-02-12 · accession 0001123292-26-000164
$1.94B
Reported value
6
Positions
2025-12-31
Period end
The Brief · GILEAD SCIENCES, INC. (GILD) · Q4 2025
AI · grounded in 13F
GILEAD SCIENCES, INC. (GILD) closed its position in MERUS N V 2GH, reducing its holdings by $42.6M. The fund also exited its position in TANGO THERAPEUTICS INC TNGX for $40.8M. Additionally, it closed its position in LEAP THERAPEUTICS INC CYPH valued at $2.4M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $748.9M | 38.7% | 31,424,760 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $550.6M | 28.4% | 16,707,477 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $438.2M | 22.6% | 6,720,803 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $153.2M | 7.92% | 4,505,391 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $38.8M | 2.00% | 4,126,119 | Common | SOLE |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $5.8M | 0.30% | 9,105,451 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.